Serum Vascular Endothelial Growth Factor after Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma.
- Author:
Ho Min JOO
1
;
Seong Woo HONG
;
Dong Hee WHANG
;
Tae Gil HEO
;
Yeo Goo CHANG
;
In Wook PAIK
;
Hyucksang LEE
Author Information
1. Department of Surgery, Seoul Paik Hospital, Inje University, Seoul, Korea. lib0196@thrunet.com
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Vascular endothelial growth factor;
Transcatheter arterial chemoembolization
- MeSH:
Angiogenesis Inducing Agents;
Anoxia;
Carcinoma, Hepatocellular*;
Humans;
Platelet Count;
Vascular Endothelial Growth Factor A*
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2003;7(1):26-31
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor. Hepatocellular carcinoma (HCC) is a typical hypervascular tumor and VEGF may play a important role in its carcinogensis and progression. Transcatheter arterial chemoembolization (TACE) which is one of the therapeutic modalities of HCC induces hypoxia to the tumor. VEGF is known to be up-regulated by hypoxia. In this study, we examined the level of VEGF in the course of TACE. METHODS: Twenty-two HCC patients were enrolled in this study. Serum VEGF level was investigated before and 1, 5 and 10 days after TACE. The correlation of clinical factors of patients and the level of serum VEGF before TACE was evaluated. Platelet count was also measured with VEGF. RESULTS: Mean serum VEGF level increased significantly 1 and 5 days after TACE. Platelet count decreased significantly 1 day after TACE. Serum VEGF level was positively correlated with platelet count before and 1 day after TACE. CONCLUSION: TACE may increase the serum level of VEGF induced by hypoxia.
